Blade beats Q2 revenue estimates, net loss narrows

Strata Critical Medical

05/08/2025 12:36

Overview

Blade Q2 2025 revenue rises 4.2%, beating analyst expectations, per LSEG data

Net loss improves to $3.7 mln, adjusted EBITDA rises to $3.2 mln

Co to sell Passenger division to Joby Aviation for up to $125 mln

Outlook

Blade reaffirms 2025 revenue guidance of $245-265 mln

Company expects divestiture to be EBITDA and cash flow neutral

Strata to focus on organic growth and capital allocation

Partnership with Joby Aviation to provide access to eVTOLs for medical flights

Result Drivers

MEDICAL SEGMENT GROWTH - Medical revenue increased 17.6% year-over-year, driven by new customers and higher revenue per block hour

PASSENGER SEGMENT DECLINE - Passenger revenue decreased due to exit from Canada and reduced demand in U.S. following a helicopter incident

COST REDUCTIONS - Improved net loss driven by $7.2 mln improvement in loss from operations and higher non-operating income

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$70.80 mln
$64.10 mln (5 Analysts)
Q2 Net Income
-$3.74 mln
Q2 Operating Expenses
$75.76 mln
Q2 Operating Income
-$4.95 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Blade Air Mobility Inc is $6.00, about 26.2% above its August 4 closing price of $4.43

Press Release: ID:nGNX18jfhD

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)